<DOC>
	<DOCNO>NCT01165307</DOCNO>
	<brief_summary>Excessive menstrual loss ( menorrhagia ) common condition affect woman reproductive age , result anemia , chronic fatigue lose wage work . The traditional first line management involve treatment oral contraceptive non-steroidal anti-inflammatory agent . Many woman ultimately undergo hysterectomy , major operative procedure associate increased cost , loss feeling womanhood , debilitate complication rare occasion , death . The new global endometrial ablation ( GEA ) device allow destruction endometrial lining , without removal uterus , ambulatory surgery setting . GEA offer safe effective alternative hysterectomy minimal risk without unpleasant side-effects . Presently , global endometrial ablation offer alternative hysterectomy , medical intervention fail . This study determine role global endometrial ablation initial management menorrhagia . Women seek treatment menorrhagia randomize either medical treatment arm global endometrial ablation arm . This study first compare clinical efficacy cost oral contraceptive pill global endometrial ablation initial management menorrhagia could potentially change management menorrhagia impact million woman suffer condition .</brief_summary>
	<brief_title>Medical Therapy Versus Radiofrequency Endometrial Ablation Initial Treatment Menorrhagia</brief_title>
	<detailed_description>Goal study : To evaluate safety , effectiveness well cost- effectiveness Global Endometrial Ablation ( GEA ) initial treatment menorrhagia . Specific aim # 1 : To determine global endometrial ablation ( GEA ) effective medical therapy initial management menorrhagia . Specific aim # 2 : To determine disease-specific resource utilization cost associate treatment alternative cost effectiveness global endometrial ablation ( GEA ) compare medical treatment ( oral contraceptive pill ) initial management menorrhagia .</detailed_description>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>1 . Adult female , ages 3055 , premenopausal childbearing complete 2 . Subjective symptom excessive menstrual loss 3 . Normal uterine cavity length ( ≥ 4cm ) sound measurement ≤10cm document sonohysterogram hysteroscopy precede 6 month 4 . At least one normal Pap Test unexplained abnormal Pap Tests within 6 month procedure 5 . Prior history permanent sterilization use reliable nonhormonal contraception 14 month study period history vasectomy partner 6 . Freely agree participate study include study related procedure evaluation , document agreement signing inform consent document 1 . Pregnancy desire future childbearing 2 . Active low genital infection time procedure 3 . Active urinary tract infection time procedure 4 . Active pelvic inflammatory disease ( PID ) recurrent chronic PID 5 . Endometrial neoplasia , determine endometrial biopsy take within 12 month study entry 6 . Current past history cervical endometrial cancer 7 . Uterine sound measurement great 10cm 8 . Submucous leiomyoma great 2cm cavity distort leiomyoma 9 . History myomectomy classical cesarean section 10 . Previous endometrial ablation 11 . Oral hormonal treatment precede 3 month , hormone release intrauterine contraceptive precede month , injectable hormone treatment precede 12 month 12 . Contraindication hormonal therapy nonsteroidal antiinflammatory agent . 13 . History coagulopathy endocrinopathy 14 . Inability follow 12 month</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Menorrhagia</keyword>
	<keyword>Endometrial ablation</keyword>
	<keyword>Heavy menstrual bleeding</keyword>
</DOC>